AMRN
AMRN clinical trials: AMARIN CORP PLC\UK
Every trial on ClinicalTrials.gov where AMARIN CORP PLC\UK is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 9
- Trials linked
- 3
- As lead sponsor
- 6
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
AMRN on the catalyst calendar · AMRN registry changes
- Primary completion Oct 2010ActualPhase 3NCT01047683Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dLAmarin Pharma Inc. · HypertriglyceridemiaCompletedAMRNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2011ActualPhase 3NCT01047501Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)Amarin Pharma Inc. · HypertriglyceridemiaCompletedAMRNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2018ActualPhase 3NCT01492361A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on StatinAmarin Pharma Inc. · Cardiovascular DiseasesCompletedAMRNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2025Sponsor estimatePhase 3NCT03428477EPA for Metastasis Trial 2Mark A Hull, PhD FRCP · Liver MetastasisActive, not recruitingAMRNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2029Sponsor estimateNo phase registeredNCT06637657Guided Optimisation of Long-term Disease rEduction in secoNdary Prevention of CVDAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Acute Coronary SyndromeRecruitingAMRNCollaboratorNVSCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 15, 2022ActualPhase 4NCT04505098A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk AdultsKaiser Permanente · Covid19TerminatedAMRNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 6, 2020ActualPhase 2NCT04412018An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19Canadian Medical and Surgical Knowledge Translation Research Group · COVID-19CompletedAMRNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2018ActualPhase 1NCT03885661Vascepa to Accelerate Lipoprotein Uptake and EliminationUniversity of Pennsylvania · Lipid DisorderCompletedAMRNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 30, 2021ActualPhase 3NCT04460651PREPARE-IT. Prevention and Treatment of COVID19 With EPA in Subjects at Risk - Intervention TrialEstudios Clínicos Latino América · COVID19CompletedAMRNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 9 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner